Intercept Pharmaceuticals (NAS:ICPT) Pre-Tax Income

: $-173.3 Mil (TTM As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Intercept Pharmaceuticals's pretax income for the three months ended in Mar. 2023 was $-31.9 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2023 was $-173.3 Mil. Intercept Pharmaceuticals's pretax margin was -46.91%.

During the past 13 years, Intercept Pharmaceuticals's highest Pretax Margin was -52.29%. The lowest was -16258.67%. And the median was -223.59%.

Intercept Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Intercept Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

-309.24

-344.68

-273.40

-136.35

-174.86

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Pre-Tax Income																-33.44	-20.32	-104.09	-17.00	-31.88

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Pre-Tax Income falls in comparison to its industry or sector. The grey bar indicates the Pre-Tax Income's extreme value range as defined by GuruFocus.

Intercept Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Intercept Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-68.216	+	-85.257	+	-18.779	+	0	+	-2.606
	=	-174.9

Intercept Pharmaceuticals's Pretax Income for the quarter that ended in Mar. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-31.632	+	2.56	+	-2.809	+	0	+	3.5527136788005E-15
	=	-31.9

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-173.3 Mil.

Intercept Pharmaceuticals (NAS:ICPT) Pre-Tax Income Explanation

Intercept Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-31.881	/	67.958
	=	-46.91%

During the past 13 years, Intercept Pharmaceuticals's highest Pretax Margin was -52.29%. The lowest was -16258.67%. And the median was -223.59%.

Intercept Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451